Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir for RSV in High-Risk Immunocompromised Patients
NCT06817889Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of remdesivir in respiratory syncytial virus infection (RSV), sponsored by Fred Hutchinson Cancer Center. Started Dec 2025; status: recruiting.
02
Drugs
remdesivir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06817889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06817889.